First, some laboratory evidence showed that patients with DM are in a state of chronic low-level inflammation: elevation of various inflammatory markers such as C-reactive protein, tumor necrosis factor and interleukin-6 [34], and this chronic low-level inflammation may lead GBS patients to poor prognosis. This evidence concerns the gene CRP and Guillain-Barre syndrome.